4//SEC Filing
Nabulsi Azmi 4
Accession 0000950170-25-031034
CIK 0001783183other
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 5:13 PM ET
Size
8.8 KB
Accession
0000950170-25-031034
Insider Transaction Report
Form 4
Nabulsi Azmi
Chief Operating Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-02-27+55,000→ 55,000 totalExercise: $5.76Exp: 2035-02-26→ Common Stock (55,000 underlying) - Award
Common Stock
2025-02-27+79,200→ 312,590 total
Holdings
- 785,700(indirect: By Trust)
Common Stock
- 3,578.93(indirect: By 401(k))
Common Stock
Footnotes (2)
- [F1]Represents restricted stock units ("RSUs") granted on February 27, 2025. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of February 27, 2025, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
- [F2]The stock option will vest with respect to 25% of the shares of common stock on February 27, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.
Documents
Issuer
Phathom Pharmaceuticals, Inc.
CIK 0001783183
Entity typeother
Related Parties
1- filerCIK 0001791412
Filing Metadata
- Form type
- 4
- Filed
- Mar 2, 7:00 PM ET
- Accepted
- Mar 3, 5:13 PM ET
- Size
- 8.8 KB